Zimbabwe has declined a significant American health deal valued at $367m (£272m) over five years over the United States' insistence on confidential data.
This rejection became public after a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "skewed".
An official spokesman has since stated that the United States was demanding access to genetic material for research and commercial purposes while refused to guarantee the benefits from future vaccines.
"We are forced to start the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged further negotiations to reach a deal acceptable to both sides so the nation's vital HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision follows a similar situation in Kenya, where a court blocked a related deal with the US after legal challenges were filed about the security of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump claimed its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to boost openness and accountability.
According to reports, 16 nations in Africa have to date agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration could have provided significant benefits for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment via US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, without any corresponding assurance of access to any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"In essence, our nation would provide the raw materials for medical research with no assurance that the final treatments would be available to our citizens should a new pandemic arise."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its push of one-on-one deals were upending frameworks previously set up via the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This mechanism is designed to ensure that when a country provides its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage further dialogue with our US partners on how subsequent co-operation might be arranged in a manner that honours the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the government's concerns, but recommended that negotiations should continue considering much of the country's Aids initiatives were funded by foreign aid.
"If specific concerns exist, including those involving data governance or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," the group commented.
The halted deal highlights the ongoing tensions between accepting vital international aid and protecting a country's data in an ever more data-driven world.